When it was announced that Nintendo was going to be released a fighting game with motion controls called Arms, many were concerned that the response wouldn’t be up to par. Based on early impressions, however, both the game and the controls seem to be performing well. This should come as a relief to fans of the Switch who might have been worried that its rise to fame might be derailed.
It’s no secret that the Nintendo Switch is on Cloud 9 right now, with the console breaking records at every turn and enthusiasm for ownership still sky high. However, even the smallest details can turn players off from a product and wonky motion controls could be a deal breaker for many. Fortunately, Kotaku and publications like it have judged that such concerns might be unwarranted.
Now, it’s worth noting that this is one game and the controls are about as straightforward as they can be. Even so, critics are still impressed by how well the characters respond to movements in order to perform three basic attacks in Arms.
For those who don’t know, Arms is basically a fighting game where players control characters who use extendable extremities to fight. Players can use both the normal controller scheme or the Joy-Con motion control and it was the latter that the reviewers focused on.
Suffice it to say, most of those who were lucky enough to test the game and the controls were surprised at how good it was. Granted, much of the excellence in the controls had a lot to do with how smart the developers were at taking advantage of the gyro-sensors, IGN notes. Whether it is punching, blocking or throwing, everything worked smoothly.
Of course, getting the hang of the controls does involve a learning curve, so players shouldn’t assume that the game will work perfectly for them without some practice. All in all, the Switch and Arms seem to perform admirably in an area where so much could have gone wrong. Players will know soon enough when the game comes out on June 16th.


Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Neuralink Expands Brain Implant Trials with 12 Global Patients
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 



